Carlos Chiesa, MD
Hematology & Oncology · Bayamon, PRNPI 1487659462
Payments from drug & device makers
Across 566 payments — averaging $29.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- E.r. Squibb & Sons, L.L.C.$2K
- AstraZeneca$2K
- Eli Lilly Export S.A. Puerto Rico Branch$1K
- R-pharm US LLC$1K
- Merck$924
- plus $4K from 32 others
What the payments were for
- Consulting fees$2,38014%
- Speaking & faculty fees$1,2007%
- Travel & lodging$120%
- Food & beverage$12,38474%
- Education$7915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 110 | $5,284 |
| E.r. Squibb & Sons, L.L.C. | 106 | $2,118 |
| AstraZeneca | 84 | $1,850 |
| Eli Lilly Export S.A. Puerto Rico Branch | 53 | $1,332 |
| R-pharm US LLC | 2 | $1,326 |
| Merck | 47 | $924 |
| PBG Puerto Rico LLC | 35 | $788 |
| AbbVie | 30 | $681 |
| Amgen | 14 | $267 |
| GSK | 11 | $247 |
| Novartis | 9 | $206 |
| Astellas Pharma US Inc | 5 | $184 |
| Beigene USA, Inc. | 7 | $164 |
| Pfizer | 5 | $159 |
| Sun Pharmaceutical Industries Inc. | 4 | $127 |
| Lilly USA, LLC | 3 | $116 |
| Seagen Inc. | 1 | $100 |
| Bayer | 4 | $95 |
| Beone Medicines USA, Inc. | 3 | $74 |
| Array Biopharma Inc | 3 | $65 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Bayer Puerto Rico Inc. | 2 | $50 |
| Hikma Pharmaceuticals USA | 3 | $49 |
| Incyte Corporation | 2 | $47 |
| Jazz Pharmaceuticals Inc. | 3 | $46 |
| Sanofi | 2 | $45 |
| Genentech USA, Inc. | 2 | $43 |
| Eisai Inc. | 1 | $43 |
| EMD Serono, Inc. | 2 | $43 |
| Stemline Therapeutics Inc. | 2 | $41 |
| Rigel Pharmaceuticals, Inc. | 2 | $39 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $27 |
| Organon | 1 | $25 |
| Sobi, Inc | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Pfizer Pharmaceuticals LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,768 in reported general payments places this provider in the 50th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 24 | $341,208 |
| XtandiEnzalutamide | 17 | $241,214 |
| Abiraterone Acetate | 25 | $53,675 |
| Imatinib Mesylate | 24 | $22,086 |
| RetacritEpoetin Alfa-Epbx | 12 | $13,033 |
| Exemestane | 11 | $909 |
| Dexamethasone | 21 | $677 |
| Oxaliplatin | 18 | $659 |
| Anastrozole | 27 | $556 |
| Ondansetron Hcl | 28 | $353 |
| Prednisone | 26 | $228 |
| Hydroxyurea | 11 | $155 |
| Rosuvastatin Calcium | 12 | $137 |
| Tramadol Hcl | 12 | $122 |
| Diphenhydramine Hcl | 12 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $116 | $341,20824 claims |
| Astellas Pharma US IncXtandi | $184 | $241,21417 claims |
| PfizerRetacrit | $159 | $13,03312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Bayamon
- Elias Sobrino NajulBayamon$323K
- Robert HunterBayamon$216K
- Yelitza RuizBayamon$28K
- Kenel Fernandez BarbosaBayamon$24K
- Juan Vazquez MedinaBayamon$20K
- Myrna Andino CamachoBayamon$20K
- Mirelis AcostaSan Juan$6.3M
- Hector Velez CortesPonce$3.1M
- Luis FloresSan Juan$2.3M
- Noridza Rivera RodriguezSan Juan$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.